SCHEMBL1629932

SCHEMBL1629932

N#Cc1ccccc1-c1ccc(N(C=O)Cc2ccccn2)c(NCCc2cccc(F)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
ADORA2A P29274 2/20 0.37
ADORA1 P30542 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GBA1 P04062 1/20 0.33
CSNK2A2 P19784 2/20 0.32
CSNK2A1 P68400 2/20 0.32
LMNA P02545 1/20 0.32
GPR84 Q9NQS5 1/20 0.32
CCNT1 O60563 1/20 0.32
RPS6KB1 P23443 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630717 0.93 KDM4E (0.43) KDM4EADORA2AADORA1NPC1RAB9A
SCHEMBL1631283 0.92 GBA1 (0.37) KDM4EADORA2AADORA1NPC1RAB9A
SCHEMBL1630876 0.90 KDM4E (0.33) KDM4EADORA2ANPC1RAB9AMEN1
SCHEMBL1632788 0.90 GRM5 (0.36) KDM4EADORA2ANPC1RAB9AMEN1
SCHEMBL1630790 0.89 GBA1 (0.35) KDM4EADORA2ANPC1RAB9AALDH1A1
SCHEMBL1630961 0.89 GABRA1 (0.33) KDM4EADORA2AMAPTGBA1LMNA
SCHEMBL1630178 0.88 CTSK (0.31) KDM4ENPC1RAB9AGBA1CSNK2A2
SCHEMBL1630593 0.88 NPC1 (0.38) KDM4EADORA2AADORA1NPC1RAB9A
SCHEMBL1632066 0.88 GPR84 (0.34) KDM4EADORA2ANPC1RAB9AMAPT
SCHEMBL1630818 0.88 NPC1 (0.33) KDM4EADORA2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US claimed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 KDM4E 3309/4885ADORA2A 2369/4885ADORA1 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.